SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5778)12/16/1998 2:59:00 PM
From: Steve Fancy  Respond to of 6136
 
Thanks Margie. Are you at the meeting. Is it over? Looks like this spin-off is viewed initially as a positive, and that it may not have all been built in. Today and tomorrow should help define where we're going. Guess I have to echo your sentiment...

GO AGPH!!

SF

PS: And I only use two exclaimation marks once or twice a year.



To: margie who wrote (5778)12/16/1998 3:02:00 PM
From: Steve Fancy  Respond to of 6136
 
Agouron Announces Approval of Divisional Stock Proposal

PR Newswire, Wednesday, December 16, 1998 at 14:48

LA JOLLA, Calif., Dec. 16 /PRNewswire/ -- At its Annual Meeting of
Shareholders today, Agouron Pharmaceuticals, Inc., (NASDAQ:AGPH) reported
that its shareholders approved the company's Divisional Stock Proposal and
other related proposals. The Divisional Stock Proposal received the
affirmative vote of the holders of a majority of all outstanding shares of
Agouron common stock. As a result, Agouron's Board of Directors is authorized
to create divisional securities separately tracking the performance of its
oncology operations and its non-oncology operations.
Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company
committed to the discovery, development, manufacturing, and marketing of
innovative therapeutic products engineered to inactivate proteins that play
key roles in cancer, AIDS, and other serious diseases.

SOURCE Agouron Pharmaceuticals, Inc.
-0- 12/16/98
/CONTACT: Donna Nichols, Vice President, Head of Corporate Communications
of Agouron Pharmaceuticals, Inc., 619-622-3009/
/Company News On-Call: prnewswire.com or fax,
800-758-5804, ext. 019650/
/Web site: agouron.com



To: margie who wrote (5778)12/16/1998 3:03:00 PM
From: Steve Fancy  Read Replies (1) | Respond to of 6136
 
The next question is when? I thought I had read mid-year '99. Thought I also remember something stating as soon as possible after the meeting.

sf


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News